Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ropinirole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 15/20 | 1.00 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 1.00 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ropinirole SCHEMBL29374522 | 1.00 | DRD2 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL4623647 | 0.99 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL1787068 | 0.99 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL16044076 | 0.99 | DRD2 (0.97) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL29366889 | 0.99 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL29278850 | 0.99 | DRD2 (0.97) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL40760 | 0.99 | APEX1 (1.00) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL28937023 | 0.97 | DRD2 (0.95) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL678982 | 0.97 | DRD2 (0.95) | DRD2DRD1DRD4DRD5DRD3 | |
| Ropinirole SCHEMBL28866728 | 0.95 | APEX1 (0.93) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23594 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| WO-2026106939-A1 | IMPROVING SYMPTOMS IN MID- TO LATE-STAGE PARKINSON'S DISEASE PATIENTS USING WITH DEEP BRAIN STIMULATION | VANDERBILT UNIVERSITY (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026102000-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS RELATED TO GLUCOSYLCERAMIDASE BETA 1 DEFICIENCY | VOYAGER THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| US-20260131140-A1 | MODIFYING EARLY-STAGE PARKINSON'S DISEASE PROGRESSION WITH DEEP BRAIN STIMULATION | VANDERBILT UNIV (US) | 2026-05-14 | — | — | US | claimed |
| CN-122028915-A | Frontotemporal lobar degenerative disease therapeutic agent and therapeutic composition | 凯制药股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| US-20260091047-A1 | THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS | NATIVE CODE BIO LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| WO-1992000735-A1 | ROPINIROLE AND DOMPERIDONE FOR USE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-01-23 | — | — | WO | claimed |
| WO-1991016306-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLONE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-10-31 | — | — | WO | claimed |
| US-4950765-A | Process | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-08-21 | — | — | US | claimed |
| US-4912126-A | Containing amine substituted in position 4 | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-27 | — | — | US | claimed |
| US-4824860-A | Treatment of Parkinsons disease | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-04-25 | — | — | US | claimed |
| CN-87105873-A | The preparation method of indoline | — | 1988-03-09 | — | — | CN | claimed |
| EP-0113964-B1 | 4-AMINOALKYL-2(3H)-INDOLONES | SMITHKLINE BECKMAN CORPORATION (US) | 1986-10-22 | — | — | EP | claimed |
| US-4588740-A | Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1986-05-13 | — | — | US | claimed |
| EP-0113964-A1 | 4-Aminoalkyl-2(3H)-indolones | SMITHKLINE BECKMAN CORPORATION (US) | 1984-07-25 | — | — | EP | claimed |
| US-4452808-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-05 | — | — | US | claimed |